Blum Robert I 4

What Happened

• Robert I. Blum, President & CEO and a director of Cytokinetics (CYTK), sold 7,500 shares in an open-market transaction on April 15, 2026. The shares were disposed at $65.38 per share for a total transaction value of $490,350. This was a sale (not a purchase or option exercise).

Key Details

• Transaction date and price: 2026-04-15 at $65.38 per share.
• Total value: $490,350.
• Transaction type/code: Open-market sale (Code S).
• Shares owned after transaction: Not specified on this Form 4.
• Footnotes: F1 indicates shares held by The Bridget Blum 2003 Irrevocable Trust; F2 indicates shares held by The Brittany Blum 2003 Irrevocable Trust.
• Filing timeliness: The Form 4 was filed with the SEC on the same date as the transaction (timely).

Context

• Sales by executives can be routine (portfolio diversification, tax planning, trust transfers) and do not by themselves indicate a change in company outlook; purchases are generally considered more informative about insider confidence.
• The filing shows the disposal and the trusts referenced in footnotes, but does not disclose any additional plan (e.g., 10b5‑1) or the insider's post-transaction total holdings.